ArticleDiabetes/metabolism research and reviews2021
Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.
Article in Diabetes/metabolism research and reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- The shared biomarkers and molecular mechanisms of systemic lupus erythematosus and type 2 diabetes.PloS one · 2026Article
- Improving Non-alcoholic Fatty Liver Disease Treatment in High-fat Diet Fed Mice with Fisetin and Hydroxychloroquine: The Cooperative Pathways for Improved Metabolic Health.Current medicinal chemistry · 2026Article
- Article
- COVID-19: Diabetes Perspective-Pathophysiology and Management.Pathogens (Basel, Switzerland) · 2023Review
- Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review).Experimental and therapeutic medicine · 2022Review
- Consequences of COVID-19 for the Pancreas.International journal of molecular sciences · 2022Review
- The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.Expert opinion on drug safety · 2021Review
- Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care.Medicina (Kaunas, Lithuania) · 2021Article
- Pharmacological management of COVID-19 in type 2 diabetes.Journal of diabetes and its complications · 2021Review
- Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa.Diabetes research and clinical practice · 2021Review
- The underlying mechanisms for severe COVID-19 progression in people with diabetes mellitus: a critical review.AIMS public health · 2021Review
- COVID-19 and diabetes mellitus: from pathophysiology to clinical management.Nature reviews. Endocrinology · 2021Review
- Lessons from COVID-19: How human behaviour may influence the science.Diabetes research and clinical practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxychloroquine has been proposed for the cure of the COVID-19 due to its anti-inflammatory and anti-viral action. People with diabetes are more prone to severe outcome if affected by COVID-19 and the use of Hydroxychloroquine might have some benefit in this setting. However, the use of Hydroxychloroquine in diabetes deserves particular attention for its documented hypoglycemic action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.